# Pizarra — PT-pseudo_259484ae733f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_259484ae733f
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.092 ng/mL²
  - PSA velocity: 1.37 ng/mL/yr
  - Prior PSA: 4.3 ng/mL
  - Prostate volume: 57.56 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.79137033 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 58 mL. csPCa 0.79.

Vitals: weight 115 kg, height 190 cm, BMI 31.9, BP 132/83 mmHg, HR 81 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2021).

Chief complaint: Current visit addresses a PSA escalation to 5.3 ng/mL against the backdrop of a prior biopsy yielding ISUP grade group 2.

History: First assessed for an elevated PSA reading in late 2023, this 65-year-old man has undergone regular serial testing since. A 30 pack-year smoking history is noted, with cessation achieved in 2021. He operates as an independent delivery driver and requested appointment times that accommodate his schedule. Married status applies, yet he resides by himself; his adult daughter acts as the main emergency contact. Lower urinary tract complaints are moderate, quantified at an IPSS of 13, and currently require no pharmacological intervention. Daily walks lasting twenty minutes form part of his routine, alongside a weekly alcohol consumption capped at two units. A 2018 knee arthroscopy stands as his only significant past surgical event, while recent memory and hearing evaluations returned normal results.

Physical examination: DRE — texture: smooth and firm; dimensions: symmetrically enlarged; palpation: negative for nodules or asymmetry. Systemic assessment shows stable vitals with no evidence of acute or chronic systemic disease.

Patient info: delivery driver; Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Memory clinic — baseline screening; Audiology — hearing test; Pulmonary function test — known COPD follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.51 +/- 0.19   (95% CI 0.15-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 7.8 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=5.3, age=65.0, psad=0.092, dre_ord=0.0, vol=57.56, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=4.0, PSA=5.3, PSA density=0.092, etc.) and could not account for the clinical context, such as the prior positive biopsy result (ISUP grade group 2) or the specific guideline criteria regarding the need for repeat biopsy after a prior positive diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of BIOPSY (p=0.51 +/- 0.19) is highly uncertain, as the statistical prior is in a 'discuss' tier, meaning it cannot distinguish between biopsy and defer. This uncertainty is amplified by the panel's internal contradiction: a prior positive biopsy (ISUP grade group 2) suggests a known diagnosis, which should shift the question from "does he have cancer" to "is the lesion stable/progressing," which the prior ignores.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - to see if the prior positive diagnosis is documented with specific follow-up plans
laboratory panel - to see if PSA density or other markers have changed since the prior biopsy
previous notes - to see if the prior positive diagnosis is documented with specific follow-up plans

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Amsterdam UMC (VUmc) Radiology | 04 January 2025
PI-RADS 4 lesion in the left peripheral zone. PSAD 0.092 ng/mL/mL. csPCa predicted probability 0.79137033.

get_psa_trend
PSA trend shows a rising trajectory: 3.3 ng/mL (Oct 2023) -> 3.7 ng/mL (Feb 2024) -> 4.2 ng/mL (May 2024) -> 4.7 ng/mL (Sep 2024) -> 5.3 ng/mL (Jan 2025).

get_previous_notes
10 Jan 2024, Dr. T. Hendriks (GP): Documented PSA trajectory climbing from 1.7 ng/mL in October 2023 to 2.7 ng/mL by February 2024. Referral arranged for comprehensive assessment due to prior positive biopsy and IPSS score of 13.

get_lab_results
PSA: 5.3 ng/mL (21 Nov 2024, H). %Free PSA: 24% (21 Nov 2024).

NOT RETRIEVED
The pathology report was not retrieved, so the specific ISUP grade group of the prior biopsy is unknown.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity is high (1.37 ng/mL/yr) and the PSA has continued to rise from 4.2 ng/mL (May 2024) to 5.3 ng/mL (Jan 2025).
- The mpMRI shows a PI-RADS 4 lesion, which is a high-risk finding, and the report does not explicitly state if this lesion is new or larger compared to prior imaging.

AGAINST sampling this patient now:
- The patient has a prior positive biopsy with an ISUP grade group 2 diagnosis, suggesting a known diagnosis.

WHERE THIS LEANS
The evidence points toward a need for further investigation due to the rising PSA and the PI-RADS 4 finding, despite the prior diagnosis. This leans toward sampling to characterize the known disease progression.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy with an ISUP grade group 2 diagnosis, the rising PSA trajectory (from 4.2 ng/mL to 5.3 ng/mL) and the PI-RADS 4 finding warrant further investigation to characterize the known disease progression. The evidence retrieved shows a clear upward trend in PSA velocity (1.37 ng/mL/yr), which suggests the need for re-sampling to guide future management decisions. The conference resolved the conflict between the prior diagnosis and the rising metrics by leaning toward sampling to characterize the known disease.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
